**Appendix 2**

|  |
| --- |
| **CASIM04\_ver1.0 Interim Clinical Commissioning Policy: Interim Clinical Commissioning Policy: Casirivimab and imdevimab in the treatment of COVID-19 in hospitalised patients – registration form for patients with hospital onset COVID-19** |
| **Patient NHS No:** |   | **Trust:** |   |
| **Patient Hospital No:** |  \* | **Practice Code:** |   |
| **Patient's Initials and DoB:** |   | **GP Postcode:** |   |
| **Consultant Name:** |   \* | **Other Contact Details:** |   \* |
| **Notification Email Address:**  (NHSE accredited domains ONLY)  |
| **Treatment Start Date:** |

|  |  |
| --- | --- |
|  |  |

 |
|  |

|  |  |
| --- | --- |
| **Please indicate whether patient meets the following criteria:** | **Please tick** |
| 1. I confirm that the patient is in hospital with SARS-CoV-2 infection which has been confirmed by a polymerase chain reaction (PCR) test within the preceding 72 hours or where a multidisciplinary team (MDT) has a high level of confidence that the clinical and/or radiological features suggest that COVID-19 is the most likely diagnosis |

|  |
| --- |
| Yes |
| No |

\* Required |
| 2. I confirm the patient was hospitalised for indications other than for the management of acute symptoms of COVID-19 |

|  |
| --- |
| Yes |
| No |

\* Required |
| 3. I confirm **one** of the following apply (please select):

|  |
| --- |
| The patient is at high risk of progression to severe COVID-19 (see Appendix 1 of the interim clinical commissioning policy for list of qualifying conditions) |
| COVID-19 infection presents a material risk of destabilising a pre-existing condition or illness or compromising recovery from surgery or other hospital procedure (as determined by multidisciplinary team [MDT] assessment) |

   |

|  |
| --- |
| Yes |
| No |

\* Required |
| 4. I confirm a baseline serum antibody test (anti-S) against SARS-CoV-2 has been taken prior to treatment administration\*\* All patients being considered for treatment with casirivimab and imdevimab for COVID-19 during their hospital stay should have their baseline serum antibody (anti-S) status measured prior to treatment, with appropriate patient consent, to support service evaluation and surveillance. |

|  |
| --- |
| Yes |
| No |

\* Required |
| 5. I confirm the patient does not meet any of the exclusion criteria listed in the interim clinical commissioning policy |

|  |
| --- |
| Yes |
| No |

\* Required |
| 6. I confirm that the patient will receive one dose of 1.2g (600mg casirivimab and 600mg imdevimab) as described in the Specialised Pharmacy Services institutional readiness document\*\*\*\* https://www.sps.nhs.uk/home/guidance/covid-19-treatments/neutralising-monoclonal-antibodies/casirivimab-and-imdevimab/ |

|  |
| --- |
| Yes |
| No |

\* Required |
| 7. I confirm that the patient will receive casirivimab and imdevimab according to the interim clinical commissioning policy\*\*\*\*\*\*\*\* As part of the policy sites are strongly encouraged to submit data through the ISARIC 4C Clinical Characterisation Protocol (CCP) case report forms (CRFs), as coordinated by the COVID-19 Clinical Information Network (CO-CIN) |

|  |
| --- |
| Yes |
| No |

\* Required |